A newer optimized CAR containing ScFv from lower affinity trastuzumab, redesigned co-stimulatory domains lower cytokine release, and use of lower affinity HER2-monoclonal antibody FRP5 for improved tumor targeting advanced to investigative stages [98]. This evidence concerns the gene ERBB2 and neoplasm.